The Geek Werks

Actos and Bladder Cancer : Bladder cancer treatment can include surgery, chemotherapy, radiation therapy, and immunotherapy. Although some of these treatments are used alone, often a combination of several treatments (i.e., both chemotherapy and surgery) is used for the most success. Selection of the most appropriate treatment is based on clinical staging, including pathological and ra­diographic information, and individual preference in close consultation with your physician. When choosing a blad­der cancer treatment, it is important that you consider not only the potential for cancer cure but also the side effects and quality of life impact of various treatments.

More information on Actos and Bladder Cancer

SURGICAL TREATMENT

Surgery plays an important role in both the staging and subsequent treatment of bladder cancer. Transurethral resection of a bladder tumor (TURBT) is the initial treat­ment step in the vast majority of patients with bladder cancer. TURBT provides valuable staging information, and pathological results from these procedures are used to make further decisions regarding what, if any, addi­tional therapy is needed. The gold standard treatment for muscle-invasive bladder cancer is radical cystectomy (removal of the bladder). Advances in surgical technique and anesthesia have reduced the complications associated with this procedure in the last two decades. The develop­ment of continent urinary diversion, which allows one to empty the bladder through the urethra, is an option for certain patients. Minimally invasive procedures such as laparoscopic or robotic-assisted radical cystectomy may also be treatment options. In addition, bladder-sparing procedures (either with partial removal of the bladder or aggressive TURBT frequently in combination with che­motherapy and/or radiation therapy) have allowed some patients to treat their cancer while leaving their blad­ders intact. Advances in surgical techniques continue to this day with the development of minimally invasive approaches to cystectomy. Both robotic-assisted and lapa­roscopic radical cystectomy have been performed safely in highly specialized centers and have the potential for decreased morbidity and a shorter period of recovery, but longer term follow-up is needed to determine if these pro­cedures are equivalent to open surgical techniques.

Information from other sources on Actos and Bladder Cancer

TURBT is often the first procedure you will have once diagnosed with a bladder tumor. This surgery is typically performed under general or spinal anesthesia as an out­patient procedure and without any incision, endoscopically through the urethra, which means a cystoscope is placed through the urethra and into the bladder. Through this scope your urologist can see the inside of your bladder and has the ability to resect, or remove, tumors in the bladder under direct vision using electrocautery. The electrocautery is also used to control bleeding after the resection is com­pleted. TURBT is extremely important for the staging of bladder tumors but can also be therapeutic for lower stage bladder cancers. Once the tumor has been removed, it can be analyzed under the microscope by a pathologist. The pathological findings dictate further treatment decisions. If the tumor is low grade and noninvasive, you will likely not need any further therapy at this point except for close follow-up.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Actos and Bladder Cancer : An intravenous pyelogram (IVP) is an X-ray study that shows the general outline of the kidneys and better detail of the collecting system than an ultra­sound. X-ray contrast is given to the patient intra­venously. The kidneys then filter and concentrate the contrast, creating an image on an X-ray taken a few minutes after the injection is given. A small tumor or stone inside the collecting system can be seen as a dark spot inside the collecting system. Historically, the IVP was a common test to evaluate upper tracts. However, due to the decreased cost of CT scans and the increased availability, it has largely been replaced by CT scanning.

CT scanners use X-rays to create a detailed image of the internal organs. The scanner takes many X-rays at once and uses a computer to combine all of the images into the one picture that you see. When getting a CT scan of the kidneys, the patient is usually scanned three times. The first scan is per­formed without contrast and will reveal any kidney stones. The second scan is performed with contrast, which helps to show tumors in the kidneys. The third scan is obtained a few minutes later, after the kidney has had time to process the contrast. The contrast fills the collecting system similar to the IVP but with greater detail. A CT scan is very good for seeing tumors in both the kidneys and the col­lecting system. In addition to the ability to see the kidneys and ureters better, the CT scan allows for visualization of the entire abdomen and lymph nodes, helping to identify metastases or unrelated diseases. Over the last several years, the cost of CT scans has come down, and the availability of scan­ners to patients has increased, making the CT scan the most common upper tract study. As with the IVP test, CT scans meant to examine the kidneys

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Although ureteroscopy is not technically an “upper tract study,” it gives us the most definitive examina­tion. It is similar to cystoscopy but uses a smaller scope. In the operating room or well-equipped office, the ureteroscope is carefully passed into the ureter as it opens into the bladder. This allows the urologist to see the inside of the ureter. It is gently passed all of the way up the ureter into the kidney. Like cys­toscopy, there are both rigid and flexible uretero- scopes. The flexible scope allows doctors to see all or most of the deep corners of the collecting system within the kidney. Biopsies of any suspicious areas can be taken and sent to pathology for analysis. Although ureteroscopy provides the best view of the collecting system, it usually requires anesthesia, and there is some small risk of damage to the kidney or ureter; thus, it is usually reserved for those patients who have had an abnormal upper tract study.

Information from other sources on Actos and Bladder Cancer

Cysview (hexaminolevulinate hydrochloride, GE health­care) has recently been approved as an optical imaging agent for use in the cystoscopic detection of non-muscle invasive papillary bladder cancer among patients sus­pected or known to have lesion(s) on the basis of prior cystoscopy. When used in combination with blue light (fluorescence) cystoscopy (Karl Storz D-Light C Pho­todynamic Diagnostic [PPD] system) it identified at least 1 more noninvasive papillary bladder tumor than rou­tine cystoscopy in about one third of the patients with such tumors. It is also useful in detecting carcinoma in situ, identifying 28% more patients with carcinoma in situ than standard cystoscopy.

Urine cytology is commonly used to screen for bladder cancer in patients who have hematuria as well as to monitor for recurrences in patients who are being treated for bladder cancer. Overall, urine cytology is able to detect 40% to 60% of bladder cancers, but the ability of cytology to detect a tumor varies depending on the grade, stage, and location of the tumor. In low-grade, low- stage tumors, cytology will detect only 25% to 40% of the tumors. It will perform better as the grade and stage of the tumor increase, with the best detection rate being for carcinoma in situ. Cytology detects approximately 90% of cases of carcinoma in situ.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : Bladder cancer is a common cancer of the urinary tract. It is the fourth leading cause of cancer-related death among men and the seventh among women. Clinical management of bladder cancer is challenging because of the heterogeneity among bladder tumors with respect to invasion and metastasis and frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treat­ments. Due to these factors it has been said that the cost per patient of bladder cancer from diagnosis to death is the highest of all cancers. In addition to it being a significant health problem, bladder cancer is an interesting cancer to study in many ways than one. For example, environmental factors such as cigarette smoking and other carcinogens play a major role in the development of transitional carci­noma of the bladder, whereas schistosomiasis, a protozoan infection, results in squamous cell carcinoma of the bladder. Different molecular pathways with distinct molecular signatures appear to be involved in the development of low-grade versus high-grade bladder tumors. Currently being monitored by an invasive endoscopic procedure, cystectomy, with urine cytology as an adjunct, bladder cancer is at the forefront of developing cancer biomarkers for noninvasive detection. Due to the differences in the invasive and metastatic potential of bladder tumors, treatment options differ depending upon the grade and stage of the tumor. New advances are being made in treatment options to improve the outcome and quality of life for patients with bladder cancer. Similarly, new molecular nomograms are being dis­covered to predict treatment outcome so that individualized treatment options can be offered to patients.

More information on Actos and Bladder Cancer

This new text book on bladder cancer is organized to give both the clinicians and laboratory investigators state-of-the art information on basic science and clinical aspects of bladder cancer. Organizing this book that includes both the molecular basis as well as clinical practices in the management of bladder cancer would not have been possible without the invaluable contributions of the authors of each chap­ter. These authors who are experts in various aspects of bladder cancer were assembled from institutions in different parts of the world. All of these authors were generous with their time and commitment for bringing the readers up-to-date infor­mation on current advances in each area of bladder cancer. In addition, these experts have provided critical evaluation of the material presented in each chapter. Therefore, as editors of this book it has been our privilege to work with each contributor and we believe that this book will serve as a comprehensive reference on bladder cancer.

Information from other sources on Actos and Bladder Cancer

Although, the readers are encouraged to read the entire book, we would like to present the highlight of each chapter in order to guide the readers to select the mate­rial of interest. Chapters 1-9 focus on molecular basis of bladder cancer, translational research into the areas of tumor markers, and standard mode of bladder diagnosis and detection. Chapters 10-22 focus on clinical aspects of bladder cancer.Smoking is well known; however, in Chap. 1 on epidemiology of bladder cancer, Dr. Ribal reminds us that other causes like occupational exposure, genetic predis­position, and infection are also linked to the development of bladder cancer. Bladder cancer is a carcinogenesis-driven cancer, with polycyclic aromatic hydro­carbons (PAH) and aromatic amines having causal links. Chapter 2 by Escudero, Shirodkar, and Lokeshwar focuses on xenobiotic metabolisms that convert PAH and aromatic amines into active carcinogens and on genetic polymorphisms that increase the risk for bladder cancer development. The chapter discusses theories of bladder cancer development (field cancerization versus clonal origin) and chromo­somal aberrations associated with bladder cancer.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : In most populations the incidence of BC is three to four times higher in men than in women (Pelucchi et al. 2006). The excess of BC in men is not fully explained by differences in smoking habits and occupation.BC is a disease of the environment and age . Populations are increasing in number, but , they are growing older as well. Since more people are living longer, more are at potential risk. Furthermore, the changing environments in developed and devel­oping countries are causing more carcinogen concentration than can be associated to genesis of BC.

Several risk factors have been proposed for BC.

More information on Actos and Bladder Cancer

Epidemiological evidence of the association between cigarette smoking and cancer began to be considered from the 1920s, and in 1950s, its relationship with lung cancer was perfectly established (Gandini et al. 2008). Tobacco smoking is cur­rently responsible for 30% of all cancer deaths in developed countries. If the current pattern of tobacco smoking continues, there will be more than one billion deaths attributable to tobacco in the twenty-first century compared with 100 million deaths in the twentieth century (Vineis et al. 2004). In the IARC Monographs of the Evaluation of Carcinogenic Risks to Humans, it is reported that there is sufficient evidence in humans that tobacco smoking causes cancer of lung, oral cavity, naso-, oro-, and hypopharynx, nasal cavity and paranasal sinuses, larynx, esophagus, stomach, pancreas, liver, kidney, ureter, urinary bladder, uterine cervix, and bone marrow (myeloid leukemia). (Sufficient evidence means that the Working group considers that a casual relationship has been established between exposure to the agent and cancer in studies in which chance, bias, and confounding could be ruled out with reasonable confidence) (International Agency for Research on Cancer 2002). Putative carcinogenic constituents of tobacco smoke include arylamines, in particular, the potent carcinogen 4-aminobiphenyl, polycyclic aromatic hydrocar­bons (PAHs), N-nitroso compounds, heterocyclic amines, and various epoxides.

Information from other sources on Actos and Bladder Cancer

Tobacco smoking is the most well-established risk factor for BC, causing around 50%-65% of male cases and 20%-30% of female cases. The lower cases in women than in men is explained by the earlier stage of the tobacco-related epidemic among European women, and it is likely to increase in the future (Boffetta 2008). In addi­tion, it has been estimated that smoking is responsible for about 34% of deaths from BC in males worldwide and for 13% of BC deaths in females. Time trends in BC incidence and mortality are consistent with those of other tobacco-related cancers, with mortality rates being highest in birth cohorts with the maximum exposure to tobacco (Maxwell 2008).

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : CAN ALL BLADDER TUMORS BE REACHED WITH A RESECTOSCOPE?

On occasion, a urologist may face an individual with a bladder tumor that cannot be reached. This is usually much more of an issue with male patients since the scope is required to pass through a much longer urethra to begin with, therefore reducing the amount of instrument available to work within the bladder. Contributing factors include:

Tumor location: tumors loeated at the dome (the very top part of the bladder or those just inside the bladder neck) may be extremely difficult to remove.

Body size: individuals who are markedly obese have distorted internal anatomy. Instruments may not be long enough to reach all bladder tumors.

Enlarged bladders: individuals with abnormally large bladders may have tumors beyond the reach of the resectoscope.

More information on Actos and Bladder Cancer

Bladder diverticulum: some bladders have an abnormal cavity called a diverticulum. If the opening to the diverticulum is small or if the diverticulum is large, bladder tumor removal may be difficult. In addition, the walls of the diverticulum are quite thin, making tumor removal more hazardous, as perforation is more likely to occur.

Information from other sources on Actos and Bladder Cancer

WHAT CAN MY UROLOGIST DO TO ENHANCE HIS ABILITY TO REMOVE TUMORS IN DIFFICULT LOCATIONS?

The experienced urologist uses several techniques to improve his chances of removing tumors that are difficult to reach. He will often keep the bladder under filled. Although this may reduce visibility, it will allow the tumor to be closer to the resectoscope. Another technique is to place manual pressure on the bladder from above. This is done by an assistant or by the urologist himself. By pushing down from above, tumors at the dome are displaced downwards. An additional technique, for the male patient, is operating through a perineal urethrostomy. The urologist makes a surgical opening into the urethra between the scrotum and rectum, allowing the resectoscope to move further into the bladder, bypassing much of the urethra.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos Bladder Cancer 12/20/2011: During phase 1 of a cancer trial, the safety of the chemotherapy dose is being determined. During the early part of the trial, a lower dose may be used. The dose is gradually increased to determine the potential for side effects. Individuals entering the trial later may receive higher doses, more potentially serious side effects, and not necessarily more effective therapy. During phase 2, it is determined how often a particular cancer will respond to the chemotherapy at a fixed dose regimen. Lastly, during phase 3, the new drug which appears to be effective is compared to the current accepted chemotherapy for a particular cancer.

For more information on Actos Bladder Cancer follow us on our RSS Feeds.

Our use of the terms Actos and Bladder, Actos Side Effects is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. “Actos” is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos and Bladder Cancer12/20/2011: When facing the prospects of chemotherapy, it is essential to have an oncologist who can inform you fully of the potential probable effectiveness of the chemotherapy being offered. Just as importantly, the toxicities of the chemotherapy must be fully reviewed. Of course, there are no absolutes when reviewing the potential for success and failure. Each individual’s cancer is unique. Some respond better than others to chemotherapy. General statistics regarding disease regression and remission are available. Absolute numbers for the individual are not.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Our use of the Terms Actos Bladder Cancer, Actos Class Action Lawsuit is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos.Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com